Skip to main content
SpringerLink
Log in

Although adverse events may occur, ‘z’-drugs and ramelteon are generally well tolerated in the treatment of insomnia

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf 2009; 32(9): 735–48

    Article  PubMed  CAS  Google Scholar 

  2. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26(4): 261–82

    Article  PubMed  CAS  Google Scholar 

  3. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59. London: BMJ Publishing Group Ltd and RPS Publishing, 2010Mar

  4. Conn DK, Madan R. Use of sleep-promoting medications in nursing home residents: risks versus benefits. Drugs Aging 2006; 23(4): 271–87

    Article  PubMed  Google Scholar 

  5. Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009; 119(6): 821–46

    Article  PubMed  CAS  Google Scholar 

  6. Vermeeren A, Danjou PE, O’Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10mg and 20mg on memory and actual driving performance. Hum Psychopharmacol Clin Exp 1998; 13Suppl. 2: S98–107

    Article  CAS  Google Scholar 

  7. Dietrich B, Emilien G, Salinas E, et al. Zaleplon does not produce residual sedation in a phase-advance model of transient insomnia [abstract]. J Sleep Res 1998; 7Suppl. 2: 67

    Google Scholar 

  8. Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 2002 Dec; 22(6): 576–83

    Article  PubMed  CAS  Google Scholar 

  9. Danjou P, Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2h before awakening. J Clin Pharmacol 1999 Sep; 48(3): 367–74

    CAS  Google Scholar 

  10. Wang-Weigand S, Zammit G, Peng X. Effect of ramelteon on middle-of-the-night balance, mobility, and memory performance in older adults [abstract]. Sleep 2007; 30 Suppl.: A244

    Google Scholar 

  11. Hajak G, Ebrahim I, Hibberd M, et al. Ramelteon, unlike zopiclone, has no effect on body sway at peak plasma levels in insomnia patients [abstract]. Sleep 2007; 30 Suppl.: A245

    Google Scholar 

  12. Soyka M, Bottlender R, Moller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 2000 Jul; 33(4): 138–41

    Article  PubMed  CAS  Google Scholar 

  13. Allain H. Arbus L, Schuck S, et al. Efficacy and safety of zolpidem administered ‘as needed’ in primary insomnia: results of a double-blind, placebo-controlled study. Clin Drug Invest 2001; 21(6): 391–400

    Article  CAS  Google Scholar 

  14. Hajak G, Muller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003 Oct; 98(10): 1371–8

    Article  PubMed  CAS  Google Scholar 

  15. Roth T, Soubrane C, Titeux L, et al. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006 Aug; 7(5): 397–406

    Article  PubMed  Google Scholar 

  16. Erman M, Krystal A, Zammit G, et al. No evidence of rebound insomnia in patients with chronic insomnia treated with zolpidem extended-release 12.5 mg administered as needed 3–7 nights/week for 6 months [abstract]. Sleep 2007; 30 Suppl.: A241–2

    Google Scholar 

  17. Rush CR, Frey JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 1999 Jul; 145(1): 39–51

    Article  CAS  Google Scholar 

  18. Bechelli LP, Navas F, Pierangelo SA. Comparison of the reinforcing properties of zopiclone and triazolam in former alcoholics. Pharmacology 1983; 27Suppl. 2: 235–41

    Article  PubMed  Google Scholar 

  19. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005; 66Suppl. 9: 31–41

    PubMed  CAS  Google Scholar 

  20. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006 Jun; 7(4): 312–8

    Article  PubMed  Google Scholar 

  21. Zammit G, Roth T, Erman M, et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia [abstract]. Sleep 2005; 28 Suppl.: A228–9

    Google Scholar 

  22. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006 Oct; 63(10): 1149–57

    Article  PubMed  CAS  Google Scholar 

  23. Physicians’ desk reference. 64th ed. Montvale (NJ): Thomson PDR, 2010

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Although adverse events may occur, ‘z’-drugs and ramelteon are generally well tolerated in the treatment of insomnia. Drugs Ther. Perspect 26, 20–23 (2010). https://doi.org/10.2165/11205200-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205200-000000000-00000

Search

Navigation